SCHEMBL1198600

SCHEMBL1198600

FC(F)(F)c1cccc(-c2nc(COC3CCCCO3)c(I)s2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 3/20 0.38
GRIN2B Q13224 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 2/20 0.38
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
ALDH1A1 P00352 4/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM4C Q9H3R0 1/20 0.36
ALPL P05186 1/20 0.35
ALPI P09923 1/20 0.35
ADORA1 P30542 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
AR P10275 1/20 0.33
TACR1 P25103 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
RAB9A P51151 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1199248 0.89 GRIN1 (0.38) GRIN1GRIN2BMEN1KMT2AMAPT
SCHEMBL1198888 0.87 GRIN1 (0.37) GRIN1GRIN2BMEN1KMT2AMAPT
SCHEMBL1199541 0.87 PPARG (0.40) GRIN1GRIN2BMEN1KMT2AMAPT
SCHEMBL1199130 0.87 MAPT (0.39) GRIN1GRIN2BMEN1KMT2AMAPT
SCHEMBL1197624 0.87 MEN1 (0.41) GRIN1GRIN2BMEN1KMT2AMAPT
SCHEMBL1198819 0.81 ALDH1A1 (0.44) GRIN1GRIN2BMEN1KMT2AMAPT
SCHEMBL2431523 0.76 GRIN1 (0.42) GRIN1GRIN2BMAPTKDM4CL3MBTL1
SCHEMBL12890243 0.76 AR (0.47) GRIN1GRIN2BMEN1KMT2AALDH1A1
SCHEMBL12876150 0.74 FFAR1 (0.36) MEN1KMT2AMAPTPPARGPPARA
SCHEMBL4811119 0.74 KDM4E (0.35) MEN1KMT2AMAPTPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A GRIN1 1913/4885GRIN2B 1748/4885MEN1 2661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.